Publication: 4694

Publication: 4694

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.

PubMed

DOI

Google Scholar

Citation:: Lancet Haematol vol 13 (9) e626-8

Year:: 2026
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Preliminary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub-ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 15

Parents:: 3648 4276
Children:: None

Program:: OGC
Primary Committee:: Lymphoma
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882, UG1CA232760, UG1CA233180, UG1CA233339, U10CA180820, UG1CA232760 (ECOG-ACRIN), U10CA180820 (ECOG-ACRIN), U10CA180888 (SWOG)

Corr. Author:
Authors:: Jeremy S Abramson Susan Geyer Sharmila Giri Levi Pederson Ann Hudson Eric D Hsi Neha Mehta-Shah Patrick M Reagan Richard L Deming Richard F Little Steven Gore Shira N Dinner Anusha Vallurupalli Daniel J Landsburg Brad Kahl Jonathan W Friedberg Nancy L Bartlett John P Leonard

Networks:: IWORC, LAPS-IL036, LAPS-MA036, LAPS-MN026, LAPS-MO011, MD001, NY018, OR013, PA075

Study: Alliance-A051701
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2/3

Keywords: